lambda – COOPER GENERAL NEWS

Viruses develop. SARS-CoV-2, the virus that causes Covid-19, is no exception. So the emergence of variants is no surprise, and not every new genetic mutation poses a serious threat.

But in recent weeks a growing drum of news coverage has started to sound the alarm about lambda, a variant first discovered in Peru late last year. The variant, initially known as C.37, quickly spread in parts of South America. On June 14, the World Health Organization classified it as an “interesting variant,” which essentially means that experts suspect it could be more dangerous than the original strain.

The prevalence of lambda and its mutations, which are similar to those found in several other highly contagious or worrying variants, make it worth watching, scientists said. But much remains unknown and it is not yet clear how high the risk is.

“I think part of the interest is just due to the fact that there is a new variant that has a new name,” said Nathaniel Landau, a microbiologist at New York University’s Grossman School of Medicine who studies the new coronavirus variants .

“But I don’t think there is any more cause for concern than before we knew about this variant,” added Dr. Landau added. So far, there is no evidence that Lambda will displace Delta, the highly transmissible variant that now dominates most of the world. “There is no reason to believe that this is now anything worse than Delta.”

Pablo Tsukayama, a microbiologist at Cayetano Heredia University in Peru who documented the creation of lambda, agreed. Latin America has “limited capacity” for genomic surveillance and laboratory follow-up studies of new variants, he said. This has created an information gap that is fueling concerns about lambda. “I don’t think it will be worse than anyone else we already have,” he said. “We know so little that it lends itself to a lot of speculation.”

According to a June 15 update by the WHO, lambda had been reported in 29 countries, territories or areas by mid-June. The variant had been detected in 81 percent of the coronavirus samples sequenced in Peru since April, and 31 percent of them in Chile so far, the agency said.

The variant accounts for less than 1 percent of samples sequenced in the United States, according to GISAID, an archive for viral genomic data. Isolated cases have been reported in some other countries.

The variant contains eight notable mutations, including seven in the gene for the spike protein found on the surface of the virus. Some of these mutations come in other flavors and could make the virus more contagious or help bypass the body’s immune response.

But big questions remain unanswered. It’s not yet clear whether lambda is more transmissible than other variants, whether it causes more serious illnesses, or makes vaccines less effective.

Updated

July 11, 2021 at 1:57 p.m. ET

“We don’t have a lot of information compared to the other variants,” says Ricardo Soto-Rifo, a virologist at the University of Chile who studied lambda.

Preliminary laboratory studies that have not yet been published in peer-reviewed journals are cause for concern and reassurance. In these studies, research teams led by Dr. Soto-Rifo and Dr. Landau found that antibodies against Lambda induced by the Pfizer, Moderna and CoronaVac vaccines are less effective than against the original strain, but are still able to neutralize the virus.

The results suggest that these vaccines should still work against lambda, the scientists said. In addition, antibodies aren’t the body’s only defense against the virus; even if they are less strong against lambda, other components of the immune system, such as T cells, can also offer protection.

“This decrease in neutralizing antibodies does not mean that the vaccine is less effective,” said Dr. Soto-Rifo. Real-world studies of how well the vaccines hold up against the variant are still needed, he said.

The researchers also reported that, like several other variants, lambda binds more tightly to cells than the original strain of the virus, making it potentially more transmissible.

Though many questions remain unanswered, Trevor Bedford, an evolutionary biologist at the Fred Hutchinson Cancer Research Center in Seattle, said that he doesn’t find lambda as worrying as Delta and doesn’t expect it to become as dominant worldwide.

“Lambda has been around for a while and it has barely made its way into the US, for example, compared to, for example, Gamma” – the variant first identified in Brazil – “which did pretty well here.” He added, “I think it did entire focus should be on Delta. “

Health workers vaccinate a woman in Peru.

DIEGO RAMOS | AFP | Getty Images

More than 18 months after the Covid-19 pandemic, the world is now used to news of new variants of the virus, especially those that have successively supplanted previous versions of the disease.

Some mutations of the virus, such as the alpha variant and the delta variant – first discovered in the UK and India respectively – were more transmissible than previous iterations of the virus and have gained worldwide acceptance. Whenever a new variant of the coronavirus emerges, scientists keep a close eye on it.

While the world is still grappling with the rapid spread of the delta variant, which the alpha variant has usurped in terms of portability and hospital admissions for unvaccinated people, there is now a new variant that is being watched by experts: the lambda -Variant.

Here’s what we know (and don’t know) about:

What is the lambda variant?

The lambda variant, or “C.37” as the lineage was called, has spread rapidly in South America, particularly Peru, where the earliest documented samples of the virus are from August 2020.

However, it was only marked as an “interesting variant” by the World Health Organization on June 14 of this year, as cases attributed to the variant had noticeably spread.

In its mid-June report, the WHO reported that “lambda has been linked to significant transmission rates in the community in several countries, with prevalence increasing over time as the incidence of Covid-19 increases” and that further research is needed this topic would be carried out variant.

Where is it exactly?

The WHO found in its June 15 report that the lambda variant was found in 29 countries, territories or areas in five WHO regions, although it is more prevalent in South America.

“Authorities in Peru reported that 81% of the Covid-19 cases sequenced since April 2021 were linked to lambda. Argentina reported an increasing prevalence of lambda since the third week of February 2021, and between April 2 and May 19 In 2021, the variant accounted for 37% of the Covid-19 cases sequenced, ”the WHO stated.

Meanwhile, in Chile, the prevalence of lambda has increased over time, accounting for 32% of the sequenced cases reported in the past 60 days, the WHO said, adding that it was floating around at rates similar to the gamma variant be, but “out competition” of the alpha variant in the same period.

According to Public Health England, the lambda variant had been detected in cases in 26 countries by June 24. These included Chile, Argentina, Peru, Ecuador, Brazil and Colombia as well as the USA, Canada, Germany, Spain, Israel, France, Great Britain and Zimbabwe.

Is it more dangerous?

The WHO and other public health authorities are trying to understand how the variant compares to other strains of the virus, including whether it could be more transmissible and more resistant to vaccines.

In mid-June, the WHO announced that “Lambda carries a number of mutations with suspected phenotypic implications, such as a potentially increased transferability or a possible increased resistance to neutralizing antibodies”.

Recalling the specific mutations in the spike protein (some of which have been described by experts as unusual), WHO said “There is currently limited evidence of the full extent of the effects associated with these genomic changes” and further studies are needed. “to better understand the impact on countermeasures [against Covid-19] and control the spread. “

It is important to note that the lambda variant is still one step down and is referred to as a “questionable variant”, like the alpha or delta mutations. In a press conference last week, the WHO technical director on Covid-19, Dr. Maria Van Kerkhove, asked what would have to happen in order to change her definition of the lambda variant.

“It would be worrying if it showed ways of increased portability, for example if it has increased severity or if it has some sort of impact on our countermeasures,” she said.

Do vaccines work against this?

Here, too, further studies are required on the effect of the lambda variant on the effectiveness of vaccines, especially in the case of vaccines widely used in the West such as those from Pfizer-BioNTech, Moderna or Oxford-AstraZeneca.

However, in parts of South America, questions have been raised about the effectiveness of Chinese vaccines, which have been used primarily in the region, as cases related to the spread of the lambda variant and infection rates rise alongside vaccination programs. Brazil, Chile and Peru all rely heavily on the Chinese Covid vaccines Sinovac or Sinopharm, but vaccination rates vary widely in South America.